OBiO Technology (Shanghai) Corp. Ltd. A
Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing pr… Read more
OBiO Technology (Shanghai) Corp. Ltd. A (688238) - Net Assets
Latest net assets as of June 2025: CN¥1.54 Billion CNY
Based on the latest financial reports, OBiO Technology (Shanghai) Corp. Ltd. A (688238) has net assets worth CN¥1.54 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.12 Billion) and total liabilities (CN¥582.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.54 Billion |
| % of Total Assets | 72.53% |
| Annual Growth Rate | 79.24% |
| 5-Year Change | 104.79% |
| 10-Year Change | N/A |
| Growth Volatility | 314.23 |
OBiO Technology (Shanghai) Corp. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how OBiO Technology (Shanghai) Corp. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OBiO Technology (Shanghai) Corp. Ltd. A (2019–2024)
The table below shows the annual net assets of OBiO Technology (Shanghai) Corp. Ltd. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.74 Billion | -15.49% |
| 2023-12-31 | CN¥2.06 Billion | -5.22% |
| 2022-12-31 | CN¥2.17 Billion | +136.65% |
| 2021-12-31 | CN¥917.67 Million | +8.03% |
| 2020-12-31 | CN¥849.45 Million | +804.41% |
| 2019-12-31 | CN¥93.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OBiO Technology (Shanghai) Corp. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27083891953.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥2.11 Billion | 121.04% |
| Total Equity | CN¥1.74 Billion | 100.00% |
OBiO Technology (Shanghai) Corp. Ltd. A Competitors by Market Cap
The table below lists competitors of OBiO Technology (Shanghai) Corp. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FONDUL PRO.GDR REGS LN-85
F:FP4G
|
$463.37 Million |
|
Plejd AB (publ)
F:3CA
|
$463.50 Million |
|
Quick Intelligent Equipment Co Ltd
SHG:603203
|
$463.63 Million |
|
Pricol Limited
NSE:PRICOLLTD
|
$463.66 Million |
|
Hovnanian Enterprises Inc
NYSE:HOV
|
$463.18 Million |
|
DAILY JOURNAL CORP.DL-01
F:DJ1
|
$463.11 Million |
|
PT Trimegah Bangun Persada Tbk
JK:NCKL
|
$463.07 Million |
|
Ricegrowers Ltd
AU:SGLLV
|
$462.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OBiO Technology (Shanghai) Corp. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,058,243,425 to 1,739,792,229, a change of -318,451,196 (-15.5%).
- Net loss of 321,813,001 reduced equity.
- Dividend payments of 6,374,929 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-321.81 Million | -18.5% |
| Dividends Paid | CN¥6.37 Million | -0.37% |
| Other Changes | CN¥9.74 Million | +0.56% |
| Total Change | CN¥- | -15.47% |
Book Value vs Market Value Analysis
This analysis compares OBiO Technology (Shanghai) Corp. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.38x to 2.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥0.90 | CN¥7.58 | x |
| 2020-12-31 | CN¥1.66 | CN¥7.58 | x |
| 2021-12-31 | CN¥1.80 | CN¥7.58 | x |
| 2022-12-31 | CN¥3.39 | CN¥7.58 | x |
| 2023-12-31 | CN¥3.18 | CN¥7.58 | x |
| 2024-12-31 | CN¥2.68 | CN¥7.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OBiO Technology (Shanghai) Corp. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -129.69%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.31x
- Recent ROE (-18.50%) is below the historical average (-8.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -43.03% | -58.05% | 0.31x | 2.41x | CN¥-45.01 Million |
| 2020 | 11.12% | 66.15% | 0.14x | 1.19x | CN¥9.49 Million |
| 2021 | 5.91% | 21.28% | 0.20x | 1.38x | CN¥-37.51 Million |
| 2022 | 1.81% | 13.48% | 0.12x | 1.15x | CN¥-177.91 Million |
| 2023 | -6.22% | -62.47% | 0.08x | 1.26x | CN¥-333.76 Million |
| 2024 | -18.50% | -129.69% | 0.11x | 1.31x | CN¥-495.79 Million |
Industry Comparison
This section compares OBiO Technology (Shanghai) Corp. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,249,192,405
- Average return on equity (ROE) among peers: 10.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OBiO Technology (Shanghai) Corp. Ltd. A (688238) | CN¥1.54 Billion | -43.03% | 0.38x | $463.33 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.28 Million | -13.04% | 0.97x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $687.82 Million | 11.47% | 1.00x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $134.48 Million | 10.88% | 3.14x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $915.76 Million | -0.65% | 0.06x | $253.71 Million |
| Chengzhi Shareholding Co Ltd (000990) | $997.75 Million | 5.11% | 1.23x | $934.96 Million |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $1.99 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $7.66 Billion | 47.23% | 0.35x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $31.94 Billion | 6.87% | 0.05x | $3.75 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $403.60 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.14 Billion | 14.05% | 0.13x | $344.80 Million |